Form 4: Vertex Pharma Officer Sells Shares After RSU Grant

Kristen Ambrose, SVP & Chief Accounting Officer at Vertex Pharmaceuticals, acquired restricted stock units and subsequently sold shares under a pre-arranged trading plan.

Summary

• Kristen Ambrose, SVP & Chief Accounting Officer of Vertex Pharmaceuticals Inc. (VRTX), reported transactions involving the company's common stock.
• On February 17, 2026, Ambrose acquired 1,809 shares of common stock as a restricted stock unit (RSU) award, which vests in installments beginning on February 20, 2027.
• Also on February 17, 2026, Ambrose disposed of 598 shares of common stock at a price of $483.75 per share, likely for tax withholding purposes related to the RSU vesting.
• Additionally, on February 17, 2026, Ambrose sold 1,557 shares of common stock at $489.46 per share.
• On February 18, 2026, Ambrose sold an additional 638 shares of common stock at $473.68 per share.
• The sales on February 17 and 18, 2026, totaling 2,195 shares, were executed pursuant to a Rule 10b5-1 trading plan established on August 8, 2025.
• Following these transactions, Ambrose's beneficial ownership of Vertex Pharmaceuticals common stock stands at 7,750 shares, a net decrease of 2,793 shares from the reported beneficial ownership after the RSU grant.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine insider transaction, with sales executed under a pre-arranged 10b5-1 plan, balancing an RSU grant with liquidity needs. It does not signal a significant positive or negative shift.

Positives

• The grant of 1,809 restricted stock units indicates continued compensation and retention of a key executive, aligning management's interests with long-term shareholder value.

Negatives

• A net reduction of 2,793 shares in beneficial ownership by a Senior Vice President and Chief Accounting Officer, even if pre-planned, represents a decrease in direct insider holdings.

Future Outlook

The restricted stock unit award granted on February 17, 2026, will vest in installments beginning on February 20, 2027.

Management Comments

• Transactions were made pursuant to Ms. Ambrose's company-approved trading plan under Rule 10b5-1, which was entered into on August 8, 2025.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those involving restricted stock unit grants and subsequent sales under Rule 10b5-1 plans, are common practices for executive compensation and personal liquidity management within the pharmaceutical industry. These pre-arranged plans are designed to allow insiders to sell shares without being accused of trading on material non-public information.

Stakeholder Impact

• Shareholders may observe a net reduction in direct insider ownership, but the pre-planned nature of the sales under a 10b5-1 plan mitigates concerns about opportunistic selling based on undisclosed information.

Next Steps

• Restricted stock units will begin vesting in installments starting February 20, 2027.

Key Dates

Recommendation

The transactions represent routine insider activity, including an RSU grant and subsequent sales under a pre-established 10b5-1 plan. This does not provide a strong signal to alter an investment position in VRTX, suggesting a 'hold' recommendation for seasoned investors.

Keywords

Vertex Pharmaceuticals, VRTX, Kristen Ambrose, Form 4, insider trading, stock sale, RSU, restricted stock units, 10b5-1 plan